Drug Pipeline
Next-generation obesity medications in development: retatrutide, orforglipron, amycretin, CagriSema, and the science behind triple-agonist therapy.
Phase 3
Retatrutide Phase 3 Data Expected by Year-End: The Triple Agonist That Could Change Everything
Eli Lilly's triple-receptor agonist (GIP + GLP-1 + glucagon) showed 24%+ weight loss in Phase 2—the highest of any obesity drug in history.
FDA Approval
Orforglipron Approved: First Oral GLP-1 Changes the Game
Daily pill at $149/month eliminates injection anxiety for 30% of eligible patients who never started GLP-1 therapy.
Upcoming
Next-Gen Drugs in the Pipeline: Amycretin, CagriSema, Survodutide
Novo Nordisk's amylin combo showed 13% loss at just 12 weeks. The next generation of obesity medications is arriving fast.
Physician-Led Program · Lion MD
Oral GLP-1 Programs
Daily pill options now available. No injections required. Full physician protocol included.
From $149/mo
Get Started →